Flash FinanceUS
After hours S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Climb Bio, Inc. (CLYM)

Climb Bio reports 70% mean PLA2R antibody reduction at Week 12 in pMN trial

Positive Impact 4 of 5 product/contract Written later

Climb Bio presented initial PrisMN Phase 2 data for budoprutug in primary membranous nephropathy at ASN Kidney Week 2026, with the 200 mg cohort showing B-cell depletion, PLA2R antibody reduction and immunologic remission at Week 12. The results were consistent with Phase 1b data, and the 600 mg cohort showed greater drug exposure and deeper B-cell suppression at Week 4, but the cohorts are small and follow-up is limited, and the company expects additional Phase 2 data in 2027.

Key points

  • 200 mg cohort: mean PLA2R antibody reduction of 70% at Week 12; five of 13 patients (38%) achieved immunologic remission
  • Patients with baseline PLA2R antibody levels below 175 RU/mL had a mean reduction of 80% at Week 12
  • 600 mg cohort: mean peripheral CD20+ B-cell suppression of 98% at Week 4, compared with 74% at 200 mg
  • Budoprutug was generally well tolerated in the 200 mg and 600 mg cohorts; no treatment-related serious adverse events were reported

The filing

CompanyClimb Bio, Inc. (CLYM)
Form8-K, current report
Filed with the SECOct 26, 2026, 6:24 AM ET
Accession number0001193125-26-430997

Items reported: 7.01 Regulation FD Disclosure8.01 Other Events

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 11:43 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on October 26, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.